PT912601E - Supressao da resposta imune via inibicao da catepsina s - Google Patents

Supressao da resposta imune via inibicao da catepsina s

Info

Publication number
PT912601E
PT912601E PT97921360T PT97921360T PT912601E PT 912601 E PT912601 E PT 912601E PT 97921360 T PT97921360 T PT 97921360T PT 97921360 T PT97921360 T PT 97921360T PT 912601 E PT912601 E PT 912601E
Authority
PT
Portugal
Prior art keywords
class
mhc
methods
cathepsin
catepsin
Prior art date
Application number
PT97921360T
Other languages
English (en)
Inventor
Hidde L Ploegh
Harold A Chapman
Richard J Riese
Paula R Wolf
Matthew S Bogyo
Original Assignee
Massachusetts Inst Technology
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21786243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT912601(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Inst Technology, Brigham & Womens Hospital filed Critical Massachusetts Inst Technology
Publication of PT912601E publication Critical patent/PT912601E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT97921360T 1996-04-22 1997-04-22 Supressao da resposta imune via inibicao da catepsina s PT912601E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1810096P 1996-04-22 1996-04-22

Publications (1)

Publication Number Publication Date
PT912601E true PT912601E (pt) 2004-04-30

Family

ID=21786243

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97921360T PT912601E (pt) 1996-04-22 1997-04-22 Supressao da resposta imune via inibicao da catepsina s

Country Status (12)

Country Link
US (4) US6608030B1 (pt)
EP (1) EP0912601B2 (pt)
JP (1) JP2000509376A (pt)
AT (1) ATE255126T1 (pt)
AU (1) AU723447B2 (pt)
CA (1) CA2251714A1 (pt)
DE (1) DE69726426T3 (pt)
DK (1) DK0912601T4 (pt)
ES (1) ES2208898T5 (pt)
NZ (1) NZ332390A (pt)
PT (1) PT912601E (pt)
WO (1) WO1997040066A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2337599A (en) * 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6204279B1 (en) * 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
JP2002517208A (ja) * 1998-06-04 2002-06-18 リプロゲン，インコーポレイティド 子宮内膜症の診断および治療におけるカテプシンの使用
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
WO2002014315A2 (en) 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
AU8125501A (en) 2000-08-14 2002-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
WO2002021129A1 (en) * 2000-09-06 2002-03-14 Ortho-Mcneil Pharmaceutical, Inc. Method of monitoring the effect of cathepsin s inhibitors
AU2001288714A1 (en) * 2000-09-06 2002-03-22 Ortho-Mcneil Pharmaceutical, Inc. A method for treating allergies
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US6780985B2 (en) * 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
JP2003287139A (ja) * 2002-03-29 2003-10-10 Uchiyama Mfg Corp ガスケット
US7101880B2 (en) * 2002-06-24 2006-09-05 Schering Aktiengesellschaft Peptidic compounds as cysteine protease inhibitors
US7319016B1 (en) 2002-08-23 2008-01-15 Takeda San Diego, Inc. Crystallization of cathepsin S
JP2006524658A (ja) * 2003-04-28 2006-11-02 ノバルティス アクチエンゲゼルシャフト カテプシンｓ阻害剤およびオピオイドを含む医薬組成物
CA2539053A1 (en) * 2003-09-23 2005-03-31 Merck Frosst Canada Ltd. Whole cell assay involving cathepsin s
JP2007513972A (ja) * 2003-12-11 2007-05-31 アクシス・ファーマシューティカルズ・インコーポレイテッド 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンｓインヒビターの使用
EP1697355A2 (en) * 2003-12-23 2006-09-06 Axys Pharmaceuticals, Inc. Amidino compounds as cysteine protease inhibitors
JP2007519744A (ja) * 2004-01-30 2007-07-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト システインプロテアーゼインヒビターとしてのシリナン化合物。
EP2010570B8 (en) * 2006-04-10 2015-01-21 Fusion Antibodies Limited Therapy against cathepsin s
US20100266577A1 (en) * 2007-07-25 2010-10-21 Felipe Samaniego Method of Cancer Treatment with Antagonists of FAS Inhibitors
WO2009054454A1 (ja) * 2007-10-24 2009-04-30 National University Corporation Tokyo Medical And Dental University カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
WO2010070615A1 (en) 2008-12-19 2010-06-24 Medivir Uk Ltd Cysteine protease inhibitors
BR112012028804A2 (pt) 2010-06-16 2016-07-26 Medivir Uk Ltd novos inibidores de protease de catepsina s, uteis no tratamento de, por exemplo, distúrbios autoimunes, alergias e condições de dores crônicas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217612B (hu) 1991-05-23 2000-03-28 Merrel Dow Pharmaceuticals Inc. Eljárás elasztáz és katepszin G inhibitor hatású peptidek előállítására
JPH08502244A (ja) 1992-08-11 1996-03-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫調節ペプチド
DK0603769T3 (da) 1992-12-25 1999-06-14 Mitsubishi Chem Corp Alfa-aminoketonderivater
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
KR19980703261A (ko) 1995-03-24 1998-10-15 다니엘 이이치. 페트리 가역성 프로테아제 억제제

Also Published As

Publication number Publication date
CA2251714A1 (en) 1997-10-30
WO1997040066A1 (en) 1997-10-30
DK0912601T4 (da) 2009-03-09
DK0912601T3 (da) 2004-03-29
DE69726426T2 (de) 2004-09-16
DE69726426T3 (de) 2009-09-10
EP0912601B1 (en) 2003-11-26
JP2000509376A (ja) 2000-07-25
US20050095248A1 (en) 2005-05-05
ES2208898T5 (es) 2009-04-16
AU723447B2 (en) 2000-08-24
DE69726426D1 (de) 2004-01-08
US20030166534A1 (en) 2003-09-04
EP0912601A1 (en) 1999-05-06
US7427591B2 (en) 2008-09-23
US20050080010A1 (en) 2005-04-14
US7285525B2 (en) 2007-10-23
AU2741897A (en) 1997-11-12
US6608030B1 (en) 2003-08-19
EP0912601B2 (en) 2008-11-05
NZ332390A (en) 2000-07-28
ES2208898T3 (es) 2004-06-16
ATE255126T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
PT912601E (pt) Supressao da resposta imune via inibicao da catepsina s
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
NO983999L (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DK1731912T3 (da) Fremgangmåde til peptidselektion
DK0870022T3 (da) Immunstimulerende sammensætning og fremgangsmåde
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DK0996726T3 (da) T-celle-membranprotein (TIRC7), peptider og antistoffer afledt deraf og anvendelse deraf
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR FIXING TAU AND MAP2c PROTEINS
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
PT782630E (pt) Gene da doenca poliquistica do rim
ATE239502T1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
Schwartz et al. External Factors, Produced by Growing Nerves, Trigger a Regenerative Response in a Non-Regenerative Central Nervous System: Purification and Mode of Action
Trainin et al. Correlation between the cellular levels of cAMP, cell-mediated immunocompetence and the thymic humoral factor (THF)
MX9700199A (es) Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes.